O	0	10	Randomized
O	11	16	phase
O	17	20	III
O	21	26	trial
O	27	29	of
B-intervention	30	36	APF530
O	37	43	versus
B-control	44	56	palonosetron
O	57	59	in
O	60	63	the
O	64	74	prevention
O	75	77	of
B-condition	78	90	chemotherapy
I-condition	90	91	-
I-condition	91	98	induced
I-condition	99	105	nausea
I-condition	106	109	and
I-condition	110	118	vomiting
O	119	121	in
O	122	123	a
O	124	130	subset
O	131	133	of
B-eligibility	134	142	patients
I-eligibility	143	147	with
I-eligibility	148	154	breast
I-eligibility	155	161	cancer
I-eligibility	162	171	receiving
I-eligibility	172	182	moderately
I-eligibility	183	185	or
I-eligibility	186	192	highly
I-eligibility	193	203	emetogenic
I-eligibility	204	216	chemotherapy
O	216	217	.

O	218	224	APF530
O	225	233	provides
O	234	244	controlled
O	244	245	,
O	246	255	sustained
O	255	256	-
O	256	263	release
O	264	275	granisetron
O	276	279	for
O	280	290	preventing
O	291	296	acute
O	297	298	(
O	298	299	0
O	299	300	-
O	300	302	24
O	303	304	h
O	304	305	)
O	306	309	and
O	310	317	delayed
O	318	319	(
O	319	321	24
O	321	322	-
O	322	325	120
O	326	327	h
O	327	328	)
O	329	341	chemotherapy
O	341	342	-
O	342	349	induced
O	350	356	nausea
O	357	360	and
O	361	369	vomiting
O	370	371	(
O	371	375	CINV
O	375	376	)
O	376	377	.

O	378	380	In
O	381	382	a
O	383	388	phase
O	389	392	III
O	393	398	trial
O	398	399	,
O	400	406	APF530
O	407	410	was
O	411	422	noninferior
O	423	425	to
O	426	438	palonosetron
O	439	441	in
O	442	452	preventing
O	453	458	acute
O	459	463	CINV
O	464	473	following
O	474	480	single
O	480	481	-
O	481	485	dose
O	486	496	moderately
O	497	498	(
O	498	501	MEC
O	501	502	)
O	503	505	or
O	506	512	highly
O	513	523	emetogenic
O	524	536	chemotherapy
O	537	538	(
O	538	541	HEC
O	541	542	)
O	543	546	and
O	547	554	delayed
O	555	559	CINV
O	560	562	in
O	563	566	MEC
O	567	568	(
O	568	571	MEC
O	572	575	and
O	576	579	HEC
O	580	587	defined
O	588	590	by
O	591	598	Hesketh
O	599	607	criteria
O	607	608	)
O	608	609	.

O	610	614	This
O	615	626	exploratory
O	627	638	subanalysis
O	639	642	was
O	643	652	conducted
O	653	655	in
O	656	659	the
O	660	666	breast
O	667	673	cancer
O	674	687	subpopulation
O	687	688	.

O	689	697	Patients
O	698	702	were
O	703	713	randomized
O	714	716	to
O	717	729	subcutaneous
O	730	736	APF530
O	737	740	250
O	741	743	or
O	744	747	500
O	748	750	mg
O	751	752	(
O	752	763	granisetron
O	764	765	5
O	766	768	or
O	769	771	10
O	772	774	mg
O	774	775	)
O	776	778	or
O	779	790	intravenous
O	791	803	palonosetron
O	804	805	0
O	805	806	.
O	806	808	25
O	809	811	mg
O	812	818	during
O	819	824	cycle
O	825	826	1
O	826	827	.

O	828	840	Palonosetron
O	841	849	patients
O	850	854	were
O	855	865	randomized
O	866	868	to
O	869	875	APF530
O	876	879	for
O	880	886	cycles
O	887	888	2
O	889	891	to
O	892	893	4
O	893	894	.

O	895	898	The
O	899	906	primary
O	907	915	efficacy
O	916	919	end
O	920	925	point
O	926	929	was
B-outcome-Measure	930	938	complete
I-outcome-Measure	939	947	response
O	948	949	(
O	949	951	CR
O	951	952	,
O	953	955	no
O	956	962	emesis
O	963	965	or
O	966	972	rescue
O	973	983	medication
O	983	984	)
O	985	987	in
O	988	993	cycle
O	994	995	1
O	995	996	.

O	997	1002	Among
O	1003	1009	breast
O	1010	1016	cancer
O	1017	1025	patients
O	1026	1027	(
O	1027	1028	n
O	1029	1030	=
B-total-participants	1031	1034	423
O	1035	1038	MEC
O	1038	1039	,
O	1040	1041	n
O	1042	1043	=
B-total-participants	1044	1047	185
O	1048	1051	HEC
O	1051	1052	)
O	1052	1053	,
O	1054	1055	>
O	1056	1058	70
O	1059	1060	%
O	1061	1069	received
O	1070	1083	anthracycline
O	1083	1084	-
O	1084	1094	containing
O	1095	1103	regimens
O	1104	1106	in
O	1107	1111	each
O	1112	1125	emetogenicity
O	1126	1134	subgroup
O	1134	1135	.

O	1136	1141	There
O	1142	1146	were
O	1147	1149	no
O	1150	1161	significant
O	1162	1169	between
O	1169	1170	-
O	1170	1175	group
O	1176	1187	differences
O	1188	1190	in
B-outcome	1191	1194	CRs
I-outcome	1195	1197	in
I-outcome	1198	1203	cycle
I-outcome	1204	1205	1
I-outcome	1206	1209	for
I-outcome	1210	1215	acute
O	1216	1217	(
O	1217	1223	APF530
O	1224	1227	250
O	1228	1230	mg
O	1230	1231	:
O	1232	1235	MEC
B-iv-bin-percent	1236	1238	71
I-iv-bin-percent	1239	1240	%
O	1240	1241	,
O	1242	1245	HEC
B-iv-bin-percent	1246	1248	77
I-iv-bin-percent	1249	1250	%
O	1250	1251	;
O	1252	1255	500
O	1256	1258	mg
O	1258	1259	:
O	1260	1263	MEC
B-iv-bin-percent	1264	1266	73
I-iv-bin-percent	1267	1268	%
O	1268	1269	,
O	1270	1273	HEC
B-iv-bin-percent	1274	1276	73
I-iv-bin-percent	1277	1278	%
O	1278	1279	;
O	1280	1292	palonosetron
O	1292	1293	:
O	1294	1297	MEC
B-cv-bin-percent	1298	1300	68
I-cv-bin-percent	1301	1302	%
O	1302	1303	,
O	1304	1307	HEC
B-cv-bin-percent	1308	1310	66
I-cv-bin-percent	1311	1312	%
O	1312	1313	)
O	1314	1317	and
B-outcome	1318	1325	delayed
O	1326	1327	(
O	1327	1333	APF530
O	1334	1337	250
O	1338	1340	mg
O	1340	1341	:
O	1342	1345	MEC
B-iv-bin-percent	1346	1348	46
I-iv-bin-percent	1349	1350	%
O	1350	1351	,
O	1352	1355	HEC
B-iv-bin-percent	1356	1358	58
I-iv-bin-percent	1359	1360	%
O	1360	1361	;
O	1362	1365	500
O	1366	1368	mg
O	1368	1369	:
O	1370	1373	MEC
B-iv-bin-percent	1374	1376	48
I-iv-bin-percent	1377	1378	%
O	1378	1379	,
O	1380	1383	HEC
B-iv-bin-percent	1384	1386	63
I-iv-bin-percent	1387	1388	%
O	1388	1389	;
O	1390	1402	palonosetron
O	1402	1403	:
O	1404	1407	MEC
B-cv-bin-percent	1408	1410	52
I-cv-bin-percent	1411	1412	%
O	1412	1413	,
O	1414	1417	HEC
B-cv-bin-percent	1418	1420	52
I-cv-bin-percent	1421	1422	%
O	1422	1423	)
B-outcome	1424	1428	CINV
O	1428	1429	.

O	1430	1435	There
O	1436	1440	were
O	1441	1443	no
O	1444	1455	significant
O	1456	1467	differences
O	1468	1470	in
O	1471	1477	within
O	1477	1478	-
O	1478	1483	cycle
O	1484	1487	CRs
O	1488	1495	between
O	1496	1502	APF530
O	1503	1508	doses
O	1509	1512	for
O	1513	1518	acute
O	1519	1522	and
O	1523	1530	delayed
O	1531	1535	CINV
O	1536	1538	in
O	1539	1542	MEC
O	1543	1545	or
O	1546	1549	HEC
O	1550	1552	in
O	1553	1559	cycles
O	1560	1561	2
O	1562	1564	to
O	1565	1566	4
O	1566	1567	;
O	1568	1571	CRs
O	1572	1579	trended
O	1580	1586	higher
O	1587	1589	in
O	1590	1595	later
O	1596	1602	cycles
O	1602	1603	,
O	1604	1608	with
O	1609	1611	no
O	1612	1619	notable
O	1620	1631	differences
O	1632	1634	in
O	1635	1642	adverse
O	1643	1649	events
O	1650	1657	between
O	1658	1664	breast
O	1665	1671	cancer
O	1672	1675	and
O	1676	1683	overall
O	1684	1695	populations
O	1695	1696	.

O	1697	1703	APF530
O	1704	1715	effectively
O	1716	1725	prevented
O	1726	1731	acute
O	1732	1735	and
O	1736	1743	delayed
O	1744	1748	CINV
O	1749	1753	over
O	1754	1755	4
O	1756	1768	chemotherapy
O	1769	1775	cycles
O	1776	1778	in
O	1779	1785	breast
O	1786	1792	cancer
O	1793	1801	patients
O	1802	1811	receiving
O	1812	1815	MEC
O	1816	1818	or
O	1819	1822	HEC
O	1822	1823	.

O	1824	1838	Clinicaltrials
O	1838	1839	.
O	1839	1842	gov
O	1843	1853	identifier
O	1853	1854	:
O	1855	1866	NCT00343460
O	1867	1868	(
O	1868	1872	June
O	1873	1875	22
O	1875	1876	,
O	1877	1881	2006
O	1881	1882	)
O	1882	1883	.
